

10 September 2013

New Company Secretary

Circadian notes that with effect from 9 September 2013 Mr Steven Zammit has resigned as Chief Financial Officer and Company Secretary. The Board acknowledges and thanks Mr Zammit for his contribution.

Circadian is pleased to announce the appointment of Mr Mark Pryn as Company Secretary and Head of Finance with immediate effect.

Mr Pryn has Chartered Company Secretarial and Chartered Accounting qualifications and his career includes various private consulting engagements (2010-2013), Company Secretary and General Manager Accounting & Treasury responsibilities with Timbercorp Limited (2001-2009), various senior financial management roles with Australian Unity (1994-2001) and previously audit manager responsibilities with Deloitte Touche Tohmatsu in both Victoria and Tasmania.

Company enquiries

Robert Klupacs

Managing Director - Circadian

Tel: +61 (0) 3 9826 0399 or

robert.klupacs@circadian.com.au

About Circadian Technologies Limited

Circadian (ASX:CIR; OTCQX:CKDXY) is a biologics drug developer focusing on cancer, cancer related and ophthalmic disease therapies. It controls exclusive worldwide rights to a significant intellectual property portfolio around Vascular Endothelial Growth Factor (VEGF)-C and -D. The applications for the VEGF technology, which functions in regulating blood and lymphatic vessel growth, are substantial and broad. Circadian's internal product development programs are primarily focused on developing VGX-100 (a human antibody against VEGF-C) as a treatment for lymphedema resulting from breast cancer treatment and solid tumours, in particular glioblastoma and colorectal cancer, as well as developing VGX-300 (soluble VEGFR-3) for 'back of the eye' disease such as wet Age Related Macular Degeneration. Circadian has also licensed rights to some parts of its intellectual property portfolio for the development of other products to ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company, including the anti-lymphatic antibody-based drug IMC-3C5 targeting VEGFR-3.